Open AccessCross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins
Author(s) -
José María Soberanes Díez,
Carolina S. Romero,
Júlia VergaraAlert,
Melissa Belló-Pérez,
Jordi Rodón,
José M. Honrubia,
Joaquím Segalés,
Isabel Sola,
Luis Enjuanes,
Rodrigo Gajardo
Publication year - 2020
Publication title -
immunotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.127
H-Index - 48
eISSN - 1750-7448
pISSN - 1750-743X
DOI - 10.2217/imt-2020-0220
Subject(s) - neutralization , antibody , intravenous immunoglobulins , covid-19 , virology , medicine , immunology , infectious disease (medical specialty) , outbreak , disease
Background: Cross-reactivity against human coronaviruses with Flebogamma ® DIF and Gamunex ® -C, two available intravenous immunoglobulins (IVIG), has been reported. In this study, these IVIG were tested for neutralization activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV). Materials & methods: Neutralization capacity of lots of IVIG manufactured prior to COVID-19 pandemic was assessed against these viruses in cell culture. Infectivity neutralization was quantified by percent reduction in plaque-forming units and/or cytopathic/cytotoxic methods. Results: All IVIG preparations showed neutralization of SARS-CoV-2 isolates. All IVIG lots produced neutralization of SARS-CoV. No IVIG preparation showed significant neutralizing activity against MERS-CoV. Conclusion: The tested IVIG contain antibodies with significant in vitro cross-neutralization capacity against SARS-CoV-2 and SARS-CoV, but not MERS-CoV. These preparations are currently under evaluation as potential therapies for COVID-19.